Regulatory News has published 1 story about SK Biopharmaceuticals on 21 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 21 September 2026.
This page is generated from Regulatory News’ editorial coverage of SK Biopharmaceuticals. It is not an advertisement.
On the record
- Company
- SK Biopharmaceuticals Co., Ltd. (KOSPI: 326030)
- Headquarters
- Seongnam-si, Gyeonggi-do, South Korea
- Founded
- 2011, spun off from SK Inc. (then SK Holdings)
- Regulator
- Japan's Ministry of Health, Labour and Welfare, via PMDA review
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
